Danielle Quarles, Mph
About Danielle Quarles, Mph
Danielle Quarles, MPH, serves as the Senior Director of Clinical Operations at Sana Biotechnology, Inc. in Arlington, Virginia, where she has worked since 2021, bringing extensive experience in clinical trial management across various therapeutic areas.
Work at Sana Biotechnology
Danielle Quarles has served as the Senior Director of Clinical Operations at Sana Biotechnology, Inc. since 2021. Her role involves overseeing clinical operations and managing various aspects of clinical trials. Based in Arlington, Virginia, she has contributed to the company's mission of advancing cell and gene therapies.
Previous Experience in Clinical Operations
Before joining Sana Biotechnology, Danielle Quarles held several positions in clinical operations across various organizations. She worked at PRA International as a Clinical Team Manager from 2011 to 2013. Prior to that, she was an Associate Manager in Clinical Trial Management at MedImmune from 2009 to 2011 and served as a Senior Clinical Research Associate at MedImmune from 2005 to 2009.
Education and Expertise
Danielle Quarles earned her Bachelor of Science degree in Animal and Poultry Sciences from Virginia Polytechnic Institute and State University, completing her studies from 1997 to 2001. She furthered her education by obtaining a Master of Public Health in Epidemiology from Johns Hopkins Bloomberg School of Public Health, where she studied from 2003 to 2007.
Achievements in Clinical Research
Danielle Quarles has received recognition for her contributions to clinical research, including the 2018 Pharma Times Clinical Researcher of the Year Gold Medal in the Team Category. Her work portfolio includes over 50 multi-million dollar clinical trials, with a focus on oncology, infectious diseases, and pulmonology. Her teams have also supported regulatory approval for five investigational products.
Specialization in Cell Therapies
Danielle Quarles has extensive experience in the field of cell therapies, including both autologous and allogeneic approaches. She has program-level oversight for several marketed CAR T therapies and has significant experience working with pediatrics and vulnerable populations in clinical settings.